sellWeak cluster of 410b5-1 plan
Alexandra Balcom sold $1.1M of NUVL
Chief Financial Officer at Nuvalent, Inc.. 11,430 shares at an average of $99.00, traded May 1, 2026, filed May 5, 2026.
Warning score
32Value
$1.1M
11,430 shares
Holdings after
85,533
-12% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +25Trade size$1.1M at market
- +5Share of holdings soldSold 12% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001862147-26-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 1, 2026 | MOption exercise Class A Common Stock10b5-1 | +7,159 | $1.08 | $7,732 | 92,692 | May 5, 2026 |
| May 1, 2026 | MOption exercise Class A Common Stock10b5-1 | +4,271 | $6.89 | $29k | 96,963 | May 5, 2026 |
| May 1, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -3,872 | $98.42 | $381k | 93,091 | May 5, 2026 |
| May 1, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -7,434 | $99.29 | $738k | 85,657 | May 5, 2026 |
| May 1, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -124 | $99.97 | $12k | 85,533 | May 5, 2026 |
| May 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,159 | $0.00 | $0 | 131,637 | May 5, 2026 |
| May 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,271 | $0.00 | $0 | 24,830 | May 5, 2026 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Nuvalent, Inc. | Henry E. Pelish Chief Scientific Officer | $261k 2,111 shares | -3% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.4M 11,430 shares | -12% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.8M 23,000 shares | -28% | |
| 16Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $679k 5,500 shares | -9% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.5M 20,000 shares | -26% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $2.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.1M 11,430 shares | -12% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $593k 5,500 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $593k 5,500 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.